Arrowstreet Capital’s Usana Health Sciences USNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $812K | Buy |
46,458
+211
| +0.5% | +$4.19K | ﹤0.01% | 1598 |
|
|
2025
Q4 | $908K | Buy |
46,247
+34,542
| +295% | +$717K | ﹤0.01% | 1575 |
|
|
2025
Q3 | $322K | Sell |
11,705
-2,113
| -15% | -$65K | ﹤0.01% | 1755 |
|
|
2025
Q2 | $422K | Buy |
+13,818
| New | +$392K | ﹤0.01% | 1780 |
|
|
2021
Q4 | – | Sell |
-80,005
| Closed | -$7.38M | – | 1745 |
|
|
2021
Q3 | $7.38M | Sell |
80,005
-101,648
| -56% | -$9.78M | 0.01% | 827 |
|
|
2021
Q2 | $18.6M | Sell |
181,653
-43,453
| -19% | -$4.36M | 0.02% | 633 |
|
|
2021
Q1 | $22M | Sell |
225,106
-300
| -0.1% | -$27.3K | 0.03% | 554 |
|
|
2020
Q4 | $17.4M | Buy |
225,406
+10,389
| +5% | +$804K | 0.02% | 640 |
|
|
2020
Q3 | $15.8M | Buy |
215,017
+7,907
| +4% | +$634K | 0.03% | 649 |
|
|
2020
Q2 | $15.2M | Buy |
207,110
+168,896
| +442% | +$13.2M | 0.03% | 611 |
|
|
2020
Q1 | $2.21M | Buy |
+38,214
| New | +$2.66M | 0.01% | 1028 |
|
|
2019
Q3 | – | Sell |
-208,237
| Closed | -$16.5M | – | 1723 |
|
|
2019
Q2 | $16.5M | Sell |
208,237
-109,118
| -34% | -$8.65M | 0.04% | 385 |
|
|
2019
Q1 | $26.6M | Sell |
317,355
-10,101
| -3% | -$1.05M | 0.06% | 294 |
|
|
2018
Q4 | $38.6M | Sell |
327,456
-2,004
| -0.6% | -$232K | 0.1% | 209 |
|
|
2018
Q3 | $39.7M | Buy |
329,460
+25,300
| +8% | +$3.14M | 0.09% | 205 |
|
|
2018
Q2 | $35.1M | Buy |
304,160
+60,141
| +25% | +$6.58M | 0.09% | 222 |
|
|
2018
Q1 | $21M | Buy |
244,019
+140,546
| +136% | +$10.9M | 0.05% | 309 |
|
|
2017
Q4 | $7.66M | Buy |
103,473
+70,917
| +218% | +$4.74M | 0.02% | 515 |
|
|
2017
Q3 | $1.88M | Sell |
32,556
-58,853
| -64% | -$3.48M | 0.01% | 717 |
|
|
2017
Q2 | $5.86M | Buy |
91,409
+80,145
| +712% | +$4.94M | 0.02% | 441 |
|
|
2017
Q1 | $649K | Buy |
+11,264
| New | +$672K | ﹤0.01% | 1051 |
|
|
2016
Q4 | – | Sell |
-15,022
| Closed | -$1.04M | – | 2512 |
|
|
2016
Q3 | $1.04M | Sell |
15,022
-11,986
| -44% | -$791K | ﹤0.01% | 1064 |
|
|
2016
Q2 | $1.5M | Sell |
27,008
-60,316
| -69% | -$3.64M | 0.01% | 913 |
|
|
2016
Q1 | $5.3M | Sell |
87,324
-210,820
| -71% | -$12.4M | 0.02% | 534 |
|
|
2015
Q4 | $19M | Sell |
298,144
-5,104
| -2% | -$331K | 0.09% | 227 |
|
|
2015
Q3 | $20.3M | Buy |
303,248
+138,522
| +84% | +$9.8M | 0.1% | 210 |
|
|
2015
Q2 | $11.3M | Buy |
164,726
+83,222
| +102% | +$5.28M | 0.06% | 248 |
|
|
2015
Q1 | $4.53M | Buy |
81,504
+3,466
| +4% | +$178K | 0.03% | 432 |
|
|
2014
Q4 | $4M | Sell |
78,038
-112,318
| -59% | -$5.51M | 0.02% | 510 |
|
|
2014
Q3 | $7.01M | Sell |
190,356
-67,426
| -26% | -$2.43M | 0.04% | 345 |
|
|
2014
Q2 | $10.1M | Sell |
257,782
-38,484
| -13% | -$1.43M | 0.05% | 298 |
|
|
2014
Q1 | $11.2M | Buy |
296,266
+91,674
| +45% | +$3.2M | 0.07% | 261 |
|
|
2013
Q4 | $7.73M | Sell |
204,592
-39,422
| -16% | -$1.51M | 0.04% | 349 |
|
|
2013
Q3 | $10.6M | Buy |
244,014
+40,036
| +20% | +$1.61M | 0.07% | 252 |
|
|
2013
Q2 | $7.38M | Buy |
+203,978
| New | +$6.2M | 0.06% | 265 |
|
Other funds holding USNA
NCM
VCM
VPM
Arrowstreet Capital's USNA Position: Q1 2026 in Review
Arrowstreet Capital increased its Usana Health Sciences (USNA) stake by 0.46% in Q1 2026, buying an estimated $4.19K and bringing the position to 46,458 shares worth $812K. The position accounts for ﹤0.01% of the portfolio, ranked #1598.
Arrowstreet Capital first reported a position in USNA in Q2 2013 and has held it in 35 quarters since. The position peaked at $39.7M in Q3 2018. 139 funds tracked by Wall St. Rank hold USNA as of Q1 2026.
- Arrowstreet Capital held 46,458 shares of Usana Health Sciences worth $812K as of Q1 2026.
- Arrowstreet Capital bought 211 Usana Health Sciences shares in Q1 2026, an estimated $4.19K.
- Usana Health Sciences made up ﹤0.01% of Arrowstreet Capital's portfolio in Q1 2026, its #1598 holding.
- Arrowstreet Capital first reported a position in Usana Health Sciences in Q2 2013 and has held it in 35 quarters since.
- Arrowstreet Capital's Usana Health Sciences position peaked at $39.7M in Q3 2018.
- 139 funds tracked by Wall St. Rank held Usana Health Sciences as of Q1 2026.
Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.